Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Brain scans sits at the center of this question for families navigating dementia.
Not yet—but they’re getting close. Blood biomarkers can now identify the biological hallmarks of Alzheimer’s disease with remarkable accuracy, and they cost a fraction of brain imaging. However, they’re not replacing PET scans entirely. Instead, they’re transforming how doctors approach diagnosis: blood tests now serve as the first line of screening, identifying who needs further imaging confirmation.
In May 2025, the FDA approved the first blood test specifically for Alzheimer’s disease—the Lumipulse G pTau217/β-Amyloid 1–42 Plasma Ratio—marking a watershed moment in how the disease is detected and managed. The most significant advantage is cost and accessibility. Amyloid PET scans, which directly visualize plaques in the brain, cost upwards of $5,000 per scan due to the need for expensive, single-use radiotracers. Blood biomarker tests, by contrast, cost between $290 and $1,150 depending on whether they’re used for initial triage or confirmation. For millions of people concerned about cognitive decline, this difference is transformative—a blood test ordered during a routine doctor’s visit replaces an expensive, specialized appointment at a scanning center.
Table of Contents
- How Do Blood Biomarkers Detect Alzheimer’s Disease?
- The Remarkable Early-Detection Window
- Cost-Effectiveness and the Triage Model
- When Blood Tests Aren’t Enough
- The Infrastructure Challenge and Access Questions
- What Do Blood Biomarkers Mean for Treatment?
- The Evolving Landscape and What’s Next
- Conclusion
How Blood Biomarkers Compare to Brain Scans for Alzheimer’s
blood biomarkers work by measuring tiny protein fragments that accumulate in the brain during Alzheimer’s disease. The two most clinically important markers are phosphorylated tau (pTau) and amyloid beta, which build up years—sometimes decades—before a person experiences memory loss or confusion. The recently approved tests measure these proteins with precision. The Lumipulse G test, approved by the FDA on May 16, 2025, measures the ratio of pTau217 to amyloid beta 1-42, achieving diagnostic accuracy greater than 93%. Elecsys pTau181, another FDA-cleared test in 2025, was specifically designed for primary care settings and helps identify which patients are unlikely to have Alzheimer’s pathology, effectively ruling out the disease in many cases.
What makes this possible is that these proteins leak into the bloodstream in measurable quantities. In the past, doctors had to directly image the brain using PET scans or wait for cognitive symptoms to appear. Now a simple blood draw, processed at a standard laboratory, can reveal what’s happening inside the brain. One example: a 58-year-old woman whose mother had Alzheimer’s can get a blood test in her primary care doctor’s office, find out whether her brain shows amyloid and tau accumulation, and begin preventive treatment if needed—all without traveling for a $5,000 scan. For cognitively normal people worried about their risk, this is a game-changer.
The Remarkable Early-Detection Window
Blood biomarkers can detect pathological changes in the brain 15 to 20 years before symptoms appear. This means someone can test positive for Alzheimer’s disease biological markers while they’re still thinking clearly and functioning normally at work and home. Traditional brain imaging couldn’t detect these early changes with the same accessibility or cost-effectiveness. Research shows that pTau217 is particularly sensitive to these earliest stages of the disease, offering a window of opportunity for intervention before irreversible cognitive decline occurs.
However, this early-detection advantage comes with an important caveat: many people with amyloid and tau in their brains never develop dementia in their lifetime. Some people’s brains are remarkably resilient, perhaps because of genetic factors, cognitive reserve, or protective lifestyle choices. A positive biomarker test means someone has pathology, but it doesn’t guarantee they’ll ever experience memory loss. This creates a psychological burden for some patients who learn they have Alzheimer’s disease pathology while feeling and functioning perfectly well. Clinicians must be skilled at communicating this distinction—having the disease’s biological signature is not the same as having the disease’s symptoms.
Cost-Effectiveness and the Triage Model
The real-world impact of blood biomarkers is unfolding through a triage model rather than complete replacement of imaging. doctors use the blood test first to identify patients likely to have Alzheimer’s pathology, then confirm findings with PET scans or cerebrospinal fluid testing only when necessary. Recent 2025-2026 cost-effectiveness data show that blood biomarker triage testing identifies 98.2% of PET-positive patients while keeping the average cost per diagnosis at $8,868 compared to $10,345 for PET scans alone. This modest savings per patient compounds across entire populations—when applied broadly, blood biomarker screening could save the healthcare system hundreds of millions of dollars while improving access for underserved communities.
A concrete example: Consider a memory clinic receiving 100 patients with mild cognitive complaints. Previously, the clinic might order PET scans for everyone—a total cost of $500,000 with scheduling delays measured in weeks. Now, they can run blood biomarker tests for $30,000-$50,000, identifying which 70 patients don’t have Alzheimer’s pathology (who can be reassured and monitored clinically) and which 30 do need imaging confirmation. This approach gets answers faster, costs less, and reduces unnecessary radiation exposure. The Elecsys pTau181 test excels at this rule-out function, telling primary care doctors when Alzheimer’s is unlikely so they can explore other causes of cognitive complaints.
When Blood Tests Aren’t Enough
Despite their power, blood biomarkers still can’t do everything brain imaging does. PET scans show the exact location and distribution of pathology in the brain—information that sometimes matters for research, predicting disease trajectory, or ruling out other conditions that might resemble Alzheimer’s. A patient with a positive blood test but an atypical pattern on imaging might actually have a different brain disease that requires different treatment. Additionally, blood biomarkers measure general brain pathology; they don’t show how much cognitive damage has already occurred.
A 70-year-old with amyloid and tau in the blood but still normal cognition has a different prognosis than an 80-year-old with the same biomarkers and already-declining memory. Insurance coverage presents another limitation. Many insurers still require demonstration of cognitive symptoms before authorizing expensive confirmatory testing, meaning a positive blood test alone isn’t always enough to trigger PET scanning or early intervention. This creates a frustrating gap where someone can have biological evidence of Alzheimer’s disease but lack access to the next step in diagnostic workup unless they pursue testing out-of-pocket or argue extensively with their insurance company. As blood biomarkers become more widely adopted, these coverage policies will likely evolve, but for now, a positive biomarker test often leads to discussion and monitoring rather than immediate advanced imaging.
The Infrastructure Challenge and Access Questions
Rolling out blood biomarker testing at scale requires building new clinical infrastructure and training. Blood tests are cheaper and faster than PET scans, but they still require drawing blood, sending it to a laboratory that performs these specialized tests, having a clinician interpret the results, and discussing implications with the patient. Many rural areas don’t have immediate access to labs equipped to run pTau217 or pTau181 tests. A patient in a small town might have an easier time getting to a regional radiology center for a PET scan than navigating the logistics of sending blood to a specialized laboratory and waiting for results.
Over time, as the tests become more common and laboratory networks expand, this will change—but the transition period requires investment. Another warning: the quality and standardization of blood biomarker tests vary across manufacturers and laboratories. Not all tests are equivalent, and clinicians ordering tests must understand which test they’re ordering and how to interpret results appropriately. The FDA-approved tests have undergone rigorous validation, but new tests emerging from research centers or international laboratories may have different performance characteristics. Patients should ask their doctors whether they’re receiving an FDA-cleared test and from which manufacturer—this information affects the reliability of the result.
What Do Blood Biomarkers Mean for Treatment?
The real value of blood biomarkers emerges when combined with disease-modifying drugs. Lecanemab and donanemab, two monoclonal antibodies targeting amyloid, can slow cognitive decline in the early stages of Alzheimer’s disease—but only in people who actually have the pathology and haven’t already progressed too far. Blood biomarkers enable doctors to identify candidates for these treatments before symptoms become disabling.
A 60-year-old with positive biomarkers but normal cognition can now begin treatment with the hope of delaying symptom onset by years. Without accessible biomarker testing, this person would likely remain untreated until cognitive decline forced them to seek medical evaluation—at which point they might be too advanced for the drugs to help. For people already experiencing mild cognitive impairment or early dementia, blood biomarker results help confirm that Alzheimer’s pathology is responsible for their symptoms and that they might benefit from these newer treatments. This clarity is important because cognitive impairment can have many causes—vitamin B12 deficiency, thyroid disease, depression, or other neurodegenerative diseases—and treating the wrong cause wastes time and delays effective intervention.
The Evolving Landscape and What’s Next
The approval of blood biomarker tests in 2025 has accelerated a shift in how Alzheimer’s disease will be detected and managed over the next five to ten years. Blood tests will likely become part of routine cognitive screening for older adults, similar to how cholesterol is screened today. This represents a fundamental change from the current model where people wait until they have obvious symptoms before seeking evaluation. Research groups worldwide are developing next-generation biomarkers that might provide even earlier detection or predict who will develop symptoms.
Some emerging work focuses on blood tests that could detect other neurodegenerative diseases—Parkinson’s, Lewy body dementia, frontotemporal dementia—bringing the same accessibility and cost advantages to other brain diseases. The long-term impact depends on whether these tests are used wisely. In the best-case scenario, widespread access to blood biomarker screening identifies people with pathology at the preclinical stage, preventive treatments become more effective, and cognitive decline is substantially reduced in future generations. In a more cautious scenario, widespread testing labels millions of cognitively normal people with “disease” status, creating anxiety and medicalization of normal aging without clear benefit. The reality will likely fall somewhere in between, with blood biomarkers becoming one of many tools clinicians use to evaluate cognitive concerns.
Conclusion
Blood biomarkers are not replacing expensive brain scans—at least not yet, and perhaps not entirely. What they’re doing is more subtle and ultimately more important: they’re making Alzheimer’s disease diagnosis accessible, affordable, and possible years before symptoms appear. The FDA-approved tests represent the first step in a triage model where blood tests identify candidates for further evaluation, reducing unnecessary imaging while improving early detection.
For patients and doctors, this means faster answers, lower costs, and the possibility of intervening early with disease-modifying treatments. If you’re concerned about cognitive decline or have a family history of Alzheimer’s disease, talking to your doctor about blood biomarker testing is now a reasonable option. These tests are most useful when interpreted in context—a positive result isn’t a diagnosis of dementia, but rather evidence that your brain shows the pathological changes associated with Alzheimer’s disease. Understanding what your blood biomarker results mean, and what they don’t mean, is the first step toward making informed decisions about your brain health.
You Might Also Like
- Could a New Blood Test Change How Alzheimer’s Is Detected?
- Why Alzheimer’s Blood Tests Are Getting So Much Attention
- What Practical Brain Health Planning Looks Like
Related reading
- why Combined Lifestyle Changes May Matter Most
- how Exercise, Diet, Sleep, and Social Life Work Together
- can Brain Health Plans Be Personalized
- why One-Size-Fits-All Dementia Advice Falls Short
- how Doctors Prioritize Dementia Risk Factors
For more on this topic, see National Institute on Aging.
